Discussion Diabetes - Type 2 Diabetes Therapy Assessment_DEC2006
December 2006

Deliverable: Transcripts Only

Objectives:

• Determine current usage/allocation of the mix of leading Type 2 therapies
• Understand utilization
• Understand physician prescribing experience with exenatide
• Assess impact of sitagliptin on treatment algorithms
• Gather impressions of inhaled insulin

Products Highlighted:

• Januvia™ (sitagliptin); Merck & Co
• Byetta® (exenatide); Amylin Pharmaceuticals/ Eli Lilly and Co
• Galvus® (vildagliptin); Novartis Pharmaceuticals
• Exubera® (insulin human [rDNA origin]); Pfizer, Inc.

Topics:

• Current Type 2 diabetes therapies and trends
• Experience and impact of Byetta
• Experience and impact of Januvia
• Expected use and impact of Galvus
• Impressions of inhaled insulins

Quotes:

• “Even though it may not induce great weight loss, it does slow weight gain. In my experience, XX% of pts may not lose any weight, YY % may still gain some weight, and ZZ% lose some weight, generally 5-10 lbs over 6 mo so far.”
• “From efficacy point does not seem to be this much effective as promised by manufacturer.”li>
• “I am actually surprised at the lukewarm response of pts to the availability of XXX.”
• “I have used YYY as a third drug (added to Metformin/TZD) in patients who have hypoglycemia with sulfonylureas.”

Screening Criteria:

• 10 Endocrinologists and Primary Care Physicians
• High-volume treaters of Type 2 diabetes
• Community practices
• Byetta prescribers and mix of Januvia users and nonusers

Representative Institutions:

• Biltmore Medical Associates
• Denville Medical
• Diabetes and Endocrinology Consultants
• Holzer Clinic
• Indianapolis Endocrinology
• Linden Medical Group
• Oak Ridge Diabetes Center
• Paradise Valley Hospital